Cargando…

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia

Pituitary adenomas with positive ACTH staining are derived from the corticotroph lineage. Most corticotroph adenomas are small and secrete ACTH, causing a form of hypercortisolism known as Cushing disease (CD); however, a subset do not secrete ACTH and are referred to as silent corticotroph adenomas...

Descripción completa

Detalles Bibliográficos
Autores principales: Castlen, Joseph, Meredith, David, Cote, David, Burke, William, De Girolami, Umberto, Pallais, J. Carl, Carroll, Rona, Laws, Edward, Kaiser, Ursula, Abreu, Ana Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550661/
http://dx.doi.org/10.1210/js.2019-MON-469
_version_ 1783424231705411584
author Castlen, Joseph
Meredith, David
Cote, David
Burke, William
De Girolami, Umberto
Pallais, J. Carl
Carroll, Rona
Laws, Edward
Kaiser, Ursula
Abreu, Ana Paula
author_facet Castlen, Joseph
Meredith, David
Cote, David
Burke, William
De Girolami, Umberto
Pallais, J. Carl
Carroll, Rona
Laws, Edward
Kaiser, Ursula
Abreu, Ana Paula
author_sort Castlen, Joseph
collection PubMed
description Pituitary adenomas with positive ACTH staining are derived from the corticotroph lineage. Most corticotroph adenomas are small and secrete ACTH, causing a form of hypercortisolism known as Cushing disease (CD); however, a subset do not secrete ACTH and are referred to as silent corticotroph adenomas (SCA). Rarely, hypercortisolemic patients who undergo surgery are diagnosed with the ill-defined entity of corticotroph hyperplasia (CH). In order to better define CH and compare the clinical, laboratory, and imaging parameters of CD, SCA, and CH, comprehensive chart review was performed for all patients at our institution within the past ten years who underwent transsphenoidal surgery for a pituitary mass showing diffuse ACTH immunostaining in lesional tissue. All cases were re-reviewed by an experienced neuropathologist to confirm the diagnoses. Patients with clinical and biochemical evidence of ACTH-dependent hypercortisolemia and an ACTH-positive adenoma were classified as CD (n=59). Patients without hypercortisolemia but with ACTH-staining adenomas were classified as SCA (n=32). Patients clinically suspected of having Cushing disease whose surgical specimen did not show adenoma but consisted only of abnormally expanded acini with ACTH-positive cells were classified as CH (n=13). Average (± SD) pre-operative cortisol (mcg/dL)/ ACTH (pg/mL) measurements were: CD 23.7±8.1 / 66.4±40.1; SCA 12.7±6.2 / 44.4±38.0; CH 24.5±5.9 / 63.8±35.1. SCA patients had larger tumors and presented with more symptoms of compression whereas both CD and CH patients presented with characteristic features of hypercortisolism: weight gain, hypertension, hirsutism, and skin changes (p<0.05 compared to SCA). Compared to CD patients, CH patients more frequently exhibited mood changes (p=0.007) and cognitive dysfunction (p=0.002). CH patients without prior pituitary surgery on average had a greater absolute number of negative late-night salivary cortisol results than CD patients (p=0.006). Of the patients with adequate follow-up, CH patients had higher cortisol levels 6 months post-operatively (p=0.007). Most patients with CH (8/13, 61.5%) had discrete lesions identified on pre-operative MRI. CD patients were more likely to have a higher MIB-1 proliferative index than those of CH patients (CD: 2.8±3.7, CH: 0.4±0.2, p=0.029). In conclusion, SCAs are more likely to cause symptoms of compression, while CD and CH cause symptoms related to hypercortisolism. There may be subtle differences between CD and CH patients, but both groups manifest with ACTH-dependent hypercortisolism and can be nearly indistinguishable pre-operatively. The difference in MIB-1 indices suggests that CH may represent a reactive or pre-neoplastic condition as opposed to undersampled adenoma. Further studies are needed to better understand the pathophysiology of corticotroph cell hyperplasia and its relation to CD.
format Online
Article
Text
id pubmed-6550661
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65506612019-06-13 MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia Castlen, Joseph Meredith, David Cote, David Burke, William De Girolami, Umberto Pallais, J. Carl Carroll, Rona Laws, Edward Kaiser, Ursula Abreu, Ana Paula J Endocr Soc Neuroendocrinology and Pituitary Pituitary adenomas with positive ACTH staining are derived from the corticotroph lineage. Most corticotroph adenomas are small and secrete ACTH, causing a form of hypercortisolism known as Cushing disease (CD); however, a subset do not secrete ACTH and are referred to as silent corticotroph adenomas (SCA). Rarely, hypercortisolemic patients who undergo surgery are diagnosed with the ill-defined entity of corticotroph hyperplasia (CH). In order to better define CH and compare the clinical, laboratory, and imaging parameters of CD, SCA, and CH, comprehensive chart review was performed for all patients at our institution within the past ten years who underwent transsphenoidal surgery for a pituitary mass showing diffuse ACTH immunostaining in lesional tissue. All cases were re-reviewed by an experienced neuropathologist to confirm the diagnoses. Patients with clinical and biochemical evidence of ACTH-dependent hypercortisolemia and an ACTH-positive adenoma were classified as CD (n=59). Patients without hypercortisolemia but with ACTH-staining adenomas were classified as SCA (n=32). Patients clinically suspected of having Cushing disease whose surgical specimen did not show adenoma but consisted only of abnormally expanded acini with ACTH-positive cells were classified as CH (n=13). Average (± SD) pre-operative cortisol (mcg/dL)/ ACTH (pg/mL) measurements were: CD 23.7±8.1 / 66.4±40.1; SCA 12.7±6.2 / 44.4±38.0; CH 24.5±5.9 / 63.8±35.1. SCA patients had larger tumors and presented with more symptoms of compression whereas both CD and CH patients presented with characteristic features of hypercortisolism: weight gain, hypertension, hirsutism, and skin changes (p<0.05 compared to SCA). Compared to CD patients, CH patients more frequently exhibited mood changes (p=0.007) and cognitive dysfunction (p=0.002). CH patients without prior pituitary surgery on average had a greater absolute number of negative late-night salivary cortisol results than CD patients (p=0.006). Of the patients with adequate follow-up, CH patients had higher cortisol levels 6 months post-operatively (p=0.007). Most patients with CH (8/13, 61.5%) had discrete lesions identified on pre-operative MRI. CD patients were more likely to have a higher MIB-1 proliferative index than those of CH patients (CD: 2.8±3.7, CH: 0.4±0.2, p=0.029). In conclusion, SCAs are more likely to cause symptoms of compression, while CD and CH cause symptoms related to hypercortisolism. There may be subtle differences between CD and CH patients, but both groups manifest with ACTH-dependent hypercortisolism and can be nearly indistinguishable pre-operatively. The difference in MIB-1 indices suggests that CH may represent a reactive or pre-neoplastic condition as opposed to undersampled adenoma. Further studies are needed to better understand the pathophysiology of corticotroph cell hyperplasia and its relation to CD. Endocrine Society 2019-04-30 /pmc/articles/PMC6550661/ http://dx.doi.org/10.1210/js.2019-MON-469 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Neuroendocrinology and Pituitary
Castlen, Joseph
Meredith, David
Cote, David
Burke, William
De Girolami, Umberto
Pallais, J. Carl
Carroll, Rona
Laws, Edward
Kaiser, Ursula
Abreu, Ana Paula
MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
title MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
title_full MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
title_fullStr MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
title_full_unstemmed MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
title_short MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
title_sort mon-469 pituitary corticotroph lesions: clinical, biochemical, and pathological characterization of cushing disease, silent corticotroph adenomas, and corticotroph hyperplasia
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550661/
http://dx.doi.org/10.1210/js.2019-MON-469
work_keys_str_mv AT castlenjoseph mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT meredithdavid mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT cotedavid mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT burkewilliam mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT degirolamiumberto mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT pallaisjcarl mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT carrollrona mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT lawsedward mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT kaiserursula mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia
AT abreuanapaula mon469pituitarycorticotrophlesionsclinicalbiochemicalandpathologicalcharacterizationofcushingdiseasesilentcorticotrophadenomasandcorticotrophhyperplasia